These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12915046)

  • 1. Sickle cell disease: loss of the blood's WD40?
    Lancaster JR
    Trends Pharmacol Sci; 2003 Aug; 24(8):389-91. PubMed ID: 12915046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombosis and sickle cell disease.
    De Franceschi L; Cappellini MD; Olivieri O
    Semin Thromb Hemost; 2011 Apr; 37(3):226-36. PubMed ID: 21455857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide pathology and therapeutics in sickle cell disease.
    Kim-Shapiro DB; Gladwin MT
    Clin Hemorheol Microcirc; 2018; 68(2-3):223-237. PubMed ID: 29614634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sickle cell anemia and vascular dysfunction: the nitric oxide connection.
    Akinsheye I; Klings ES
    J Cell Physiol; 2010 Sep; 224(3):620-5. PubMed ID: 20578237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology and treatment of sickle cell disease.
    Raphael RI
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):492-505. PubMed ID: 16167028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood feud: keeping hemoglobin from nixing NO.
    Liao JC
    Nat Med; 2002 Dec; 8(12):1350-1. PubMed ID: 12457171
    [No Abstract]   [Full Text] [Related]  

  • 7. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease--mechanisms and consequences.
    Aslan M; Freeman BA
    Cell Mol Biol (Noisy-le-grand); 2004 Feb; 50(1):95-105. PubMed ID: 15040433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.
    Reiter CD; Wang X; Tanus-Santos JE; Hogg N; Cannon RO; Schechter AN; Gladwin MT
    Nat Med; 2002 Dec; 8(12):1383-9. PubMed ID: 12426562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.
    Canalli AA; Franco-Penteado CF; Saad ST; Conran N; Costa FF
    Haematologica; 2008 Apr; 93(4):605-9. PubMed ID: 18326523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sickle cell disease vasculopathy: a state of nitric oxide resistance.
    Wood KC; Hsu LL; Gladwin MT
    Free Radic Biol Med; 2008 Apr; 44(8):1506-28. PubMed ID: 18261470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea.
    Almeida CB; Souza LE; Leonardo FC; Costa FT; Werneck CC; Covas DT; Costa FF; Conran N
    Blood; 2015 Aug; 126(6):711-20. PubMed ID: 26019278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiological insights in sickle cell disease.
    Odièvre MH; Verger E; Silva-Pinto AC; Elion J
    Indian J Med Res; 2011 Oct; 134(4):532-7. PubMed ID: 22089617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spin label study of hemoglobin membrane interactions in normal and sickle erythrocytes.
    Jones GL
    Proc West Pharmacol Soc; 1979; 22():79-86. PubMed ID: 515098
    [No Abstract]   [Full Text] [Related]  

  • 14. Carbamylation distributions in extracorporeal treatment of sickle cell anemia.
    Uvelli DA; Agodoa LC; Babb AL
    J Lab Clin Med; 1978 Jun; 91(6):939-47. PubMed ID: 650059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in sickle cell disease].
    de Montalembert M
    Bull Acad Natl Med; 2008 Oct; 192(7):1375-81; discussion 1381. PubMed ID: 19445363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts).
    Dean J; Schechter AN
    N Engl J Med; 1978 Oct; 299(15):804-11. PubMed ID: 692564
    [No Abstract]   [Full Text] [Related]  

  • 17. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
    Wood KC; Granger DN
    Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we just say NO to sickle cell anemia?
    Nagel RL
    J Clin Invest; 1999 Oct; 104(7):847-8. PubMed ID: 10510323
    [No Abstract]   [Full Text] [Related]  

  • 19. Ability of sickle cells to scavenge endothelium-derived nitric oxide is reduced.
    Olmos L; Mombouli JV; Wasserstrum N; Vanhoutte PM
    Acta Pharmacol Sin; 2002 Nov; 23(11):967-73. PubMed ID: 12421471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of hemoglobin carbamylation on the survival of human sickle cell erythrocytes in rats.
    Castro O; Orlin J; Finch SC
    Yale J Biol Med; 1974 Mar; 47(1):55-60. PubMed ID: 4825087
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.